Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
OKYO
#6046
OKYO Pharma Limited Ordinary Shares
1.7
1
0.00%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
0.00%
Monthly Change
-23.32%
6 month change
-24.67%
Year Change
+44.92%
Previous Close
1.7
1
Open
1.7
1
Bid
Ask
Low
1.7
1
High
1.7
1
Volume
2
Markets
US Stock Market
Healthcare
OKYO
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
37.61 M
—
Valuation ratios
Enterprise value
47.77 M
—
Price to earnings ratio
—
—
Price to sales ratio
—
—
Price to cash flow ratio
—
—
Price to book ratio
—
—
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
—
—
Return on equity %
—
—
Return on invested capital %
—
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
—
—
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
—
—
Long term debt to total equity ratio
—
—
Per share metrics
Operating cash flow per share
—
—
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
—
—
Net current asset value per share
—
—
Tangible book value per share
—
—
Working capital per share
—
—
Book value per share
—
—
News
Piper Sandler initiates OKYO Pharma stock with Overweight rating
OKYO Pharma stock tumbles on $20 million public offering announcement
OKYO Pharma announces $20 million public offering of ordinary shares
OKYO Pharma transitions ATM equity offering to Leerink Partners as sales agent
OKYO Pharma appoints former Dompé CMO Flavio Mantelli to lead NCP program
OKYO Pharma to present urcosimod NCP study results at ASCRS meeting
H.C. Wainwright reiterates Buy rating on OKYO Pharma stock with $7 price target
OKYO Pharma stock rises after FDA confirms Phase 2b/3 trial design
OKYO Pharma reports successful FDA meeting on urcosimod clinical trial
OKYO Pharma receives FDA alignment on Phase 2b/3 trial for NCP treatment
OKYO Pharma stock gets FDA compassionate use approval for urcosimod
FDA authorizes compassionate use of urcosimod for neuropathic corneal pain